Anixa Biosciences (ANIX) Stock Analysis & Winston Score

Anixa Biosciences is a small biotechnology company focused on developing treatments and vaccines for cancer. Its main programs include a breast cancer vaccine being developed in partnership with Cleveland Clinic, and a CAR-T cell therapy targeting ovarian cancer. The company does not yet sell any approved products — it is still in the research and clinical trial stage. Anixa makes no product revenue today and funds its operations primarily through equity financing, meaning it regularly sells new shares to raise cash. It operates in the United States and is considered a clinical-stage company, which means all spending goes toward research rather than generating profits. The negative ROIC reflects this pre-revenue reality. The key risk is that clinical trials are expensive and uncertain — if its cancer vaccine or CAR-T programs fail to show strong results in trials, the company could struggle to survive without raising more capital or finding a larger partner.